UiPath (NYSE:PATH) Trading Down 1.5%

UiPath Inc. (NYSE:PATH) traded down 1.5% on Wednesday . The stock traded as low as $19.59 and last traded at $19.71. 1,084,585 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 8,297,682 shares. The stock had previously closed at $20.02.

Analyst Ratings Changes

A number of brokerages have weighed in on PATH. Canaccord Genuity Group lifted their price target on shares of UiPath from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, March 15th. Mizuho boosted their price target on UiPath from $22.00 to $25.00 and gave the stock a “neutral” rating in a research note on Thursday, March 14th. Royal Bank of Canada restated a “sector perform” rating and set a $29.00 price objective on shares of UiPath in a report on Monday, April 1st. DA Davidson increased their target price on UiPath from $20.00 to $24.00 and gave the company a “neutral” rating in a research note on Thursday, March 14th. Finally, Scotiabank lifted their price target on shares of UiPath from $29.00 to $30.00 and gave the stock a “sector perform” rating in a research note on Thursday, March 14th. Nine research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $27.41.

UiPath Trading Down 0.6 %

The company has a market capitalization of $11.32 billion, a price-to-earnings ratio of -117.06 and a beta of 1.01. The firm has a 50-day moving average price of $21.60 and a 200-day moving average price of $21.78.

UiPath (NYSE:PATH) last posted its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.10. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. The company had revenue of $405.25 million during the quarter, compared to analyst estimates of $383.32 million. Equities research analysts predict that UiPath Inc. will post -0.04 EPS for the current fiscal year.

Insider Buying and Selling

In other UiPath news, CFO Ashim Gupta sold 40,000 shares of the business’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $21.66, for a total transaction of $866,400.00. Following the sale, the chief financial officer now owns 660,762 shares in the company, valued at approximately $14,312,104.92. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 31.03% of the company’s stock.

Institutional Trading of UiPath

Several large investors have recently added to or reduced their stakes in the company. Xponance Inc. raised its position in UiPath by 3.9% during the third quarter. Xponance Inc. now owns 44,846 shares of the healthcare company’s stock valued at $767,000 after buying an additional 1,694 shares during the period. Raymond James & Associates increased its holdings in shares of UiPath by 51.0% in the 3rd quarter. Raymond James & Associates now owns 89,534 shares of the healthcare company’s stock valued at $1,532,000 after purchasing an additional 30,244 shares during the period. Bank of New York Mellon Corp lifted its position in shares of UiPath by 0.6% in the third quarter. Bank of New York Mellon Corp now owns 2,385,317 shares of the healthcare company’s stock worth $40,813,000 after purchasing an additional 15,334 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of UiPath by 27.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 94,499 shares of the healthcare company’s stock worth $1,617,000 after purchasing an additional 20,491 shares during the period. Finally, Mackenzie Financial Corp purchased a new position in UiPath during the third quarter valued at approximately $2,359,000. 62.50% of the stock is owned by institutional investors and hedge funds.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.